Comerica Bank Acquires 22,079 Shares of Solventum Corporation $SOLV

Key Points

• Comerica Bank increased its holdings in Solventum Corporation by 39.7% during the 1st quarter, holding 77,725 shares valued at approximately $5.91 million.
• Multiple institutional investors, including Trian Fund Management and Independent Franchise Partners, significantly raised their stakes in Solventum, indicating strong institutional interest in the company.
• Analyst ratings for Solventum are mixed, with four analysts recommending a Buy, while the overall consensus rating remains a Hold with an average target price of $85.75.

Comerica Bank boosted its holdings in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 39.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,725 shares of the company's stock after acquiring an additional 22,079 shares during the period. Comerica Bank's holdings in Solventum were worth $5,910,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Clarity Asset Management Inc. purchased a new position in Solventum during the 4th quarter valued at about $25,000. Rossby Financial LCC purchased a new position in Solventum during the 1st quarter valued at about $25,000. Strengthening Families & Communities LLC lifted its position in Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock valued at $25,000 after acquiring an additional 260 shares during the period. Raiffeisen Bank International AG purchased a new position in Solventum during the 4th quarter valued at about $29,000. Finally, Colonial Trust Co SC lifted its position in Solventum by 240.7% during the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company's stock valued at $34,000 after acquiring an additional 361 shares during the period.

Solventum Stock Performance

Shares of SOLV stock traded down $1.79 during trading hours on Tuesday, reaching $71.30. The company had a trading volume of 448,059 shares, compared to its average volume of 1,077,086. The business has a fifty day moving average price of $73.76 and a 200-day moving average price of $72.80. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92. The firm has a market cap of $12.36 billion, a PE ratio of 33.02, a price-to-earnings-growth ratio of 1.77 and a beta of 0.53. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts' consensus estimates of $1.45 by $0.24. The firm had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Morgan Stanley raised shares of Solventum from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Piper Sandler restated an "overweight" rating and set a $94.00 price objective (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Wells Fargo & Company raised their price objective on shares of Solventum from $75.00 to $79.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Solventum from a "buy" rating to a "strong-buy" rating in a research note on Monday. Finally, KeyCorp began coverage on shares of Solventum in a research note on Friday, June 6th. They set a "sector weight" rating for the company. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $85.75.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.